195 filings
Page 4 of 10
8-K
ar8kchzoj48ia cc65
21 Mar 22
Regulation FD Disclosure
7:06am
S-8
cutjg6oqmqzp8yutc2t
24 Feb 22
Registration of securities for employees
7:26am
POS AM
bzsai8y150 z3eeah
24 Feb 22
Prospectus update (post-effective amendment)
7:20am
POSASR
154flebfqspj5zr
24 Feb 22
Automatic shelf registration (post-effective amendment)
7:12am
8-K
tajqkcjy0enrxbjl
24 Feb 22
Provention Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
7:07am
8-K
3713qu3z1i xbxyj71
22 Feb 22
Regulation FD Disclosure
7:45am
8-K
saqh32dgla0xx3t2b
27 Jan 22
Provention Bio Resubmitting Biologics License Application for Delay of Clinical Type 1
4:14pm
8-K
mm3rcek 0u9xnf
22 Nov 21
Provention Bio Provides Regulatory Update for Teplizumab At-Risk Type 1 Diabetes Approval Pathway
7:40am
8-K
buezp
4 Nov 21
Provention Bio Reports Third Quarter 2021 Financial Results and Provides Business Update
7:14am
8-K
h7r5w5mlk42l9wrf7r
5 Aug 21
Provention Bio Reports Second Quarter 2021 Financial Results and Provides Business Update
7:16am
8-K
juegd6txxd750hzm05
6 Jul 21
Previously reported pharmacokinetic (PK) drug product comparability considerations remain outstanding
7:14am
8-K
cfu1pd
27 May 21
If approved, teplizumab will be the first disease-modifying therapy in T1D
9:55pm
8-K
mv80z
25 May 21
Provention Bio Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Teplizumab
9:36am
8-K
h1f5 hwyqzy5pkppt
14 May 21
Amendments to Articles of Incorporation or Bylaws
4:17pm
8-K
g68vx fkxci8
6 May 21
Provention Bio Reports First Quarter 2021 Financial Results and Provides Business Update
7:24am